CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sigilon Therapeutics, Inc., a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today announced that Chief Executive Officer, Rogerio Vivaldi, M.D., will participate in three upcoming virtual investor conferences.
Presentation Details:
Event: BTIG Virtual Biotechnology Conference
Date: Monday, August 10, 2020
Time: 9:00 AM ET
Details: Fireside chat
Event: Canaccord Genuity 40th Annual Growth Conference
Date: Thursday, August 13, 2020
Time: 1:30 PM ET
Details: Corporate presentation
Event: Oppenheimer Private Life Sciences Company Call Series
Date: Wednesday, August 19, 2020
Time: 9:30 AM ET
Details: Corporate presentation
About Sigilon Therapeutics
Sigilon Therapeutics seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform. Sigilon’s product candidates consist of novel human cells engineered to produce the crucial proteins, enzymes or factors needed by patients living with chronic diseases such as hemophilia, diabetes and lysosomal disorders. The engineered cells are protected by Sigilon’s Afibromer™ biomaterials matrix, which shields them from immune rejection and fibrosis. Sigilon was founded by Flagship Pioneering in conjunction with Daniel Anderson, Ph.D., and Robert Langer, Sc.D., of the Massachusetts Institute of Technology.
Contacts
Investor Contact
Glenn Reicin
Sigilon Therapeutics, Chief Financial Officer
glenn.reicin@sigilon.com
646-696-4344
Media Contact
Amy Bonanno
Solebury Trout
abonanno@troutgroup.com
914-450-0349